Merrimack Pharmaceut (MACK) 4.53 $MACK Biotech
Post# of 273257
Posted On: 09/03/2016 9:20:30 PM
Merrimack Pharmaceut (MACK) 4.53 $MACK
Biotech Stocks on Investors' Radar -- Alexion Pharma, BioMarin Pharma, Merrimack Pharma, and Pacific Biosciences of California
PR Newswire - Wed Aug 31, 6:50AM CDT
Stock-Callers.com's focus shifted to Biotechnology industry which uses biological systems or living organisms for the development of biopharmaceutical drugs. Two main catalysts driving stocks in this arena are clinical and regulatory developments. Let us now review today's featured companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), and Pacific Biosciences of California Inc. (NASDAQ: PACB). Learn more about these stocks by downloading their comprehensive and free reports at:
MACK: 4.53 (-0.06), PACB: 8.28 (-0.02), BMRN: 95.73 (+0.54), ALXN: 123.67 (-1.96)
What Makes Merrimack Pharmaceuticals (MACK) a Strong Sell?
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:50AM CDT
Merrimack Pharmaceuticals (MACK) has witnessed a significant price decline in the past four weeks, and it has lately seen negative earnings estimate revisions as well.
MACK: 4.53 (-0.06)
Potash Corporation of Saskatchewan, The Hain Celestial Group, Williams Companies, Cisco Systems, and Merrimack Pharmaceuticals and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Mon Aug 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CSCO, HAIN, MACK, POT, and WMB.
MACK: 4.53 (-0.06), HAIN: 36.65 (+0.43), POT: 17.99 (+0.18), WMB: 28.40 (+0.25), CSCO: 31.83 (+0.25)
Merrimack (MACK) Q2 Loss Wider than Expected, Sales Top
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 3:02PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 40 cents per share in the second quarter of 2016, wider than the Zacks Consensus Estimate of 34 cents.
MACK: 4.53 (-0.06)
Covered Call reports for Valeant Pharmaceuticals, Merrimack Pharmaceuticals, Exelixis, Under Armour and Harman International Industries include trade ideas that offer returns of 20% or more!
PR Newswire - Fri Aug 05, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for EXEL, HAR, MACK, UA, and VRX.
MACK: 4.53 (-0.06), UA: 38.56 (-1.19), VRX: 28.76 (-0.36), HAR: 85.99 (+1.17), EXEL: 11.54 (+0.19)
Merrimack Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Aug 04, 3:01PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced its second quarter 2016 financial results. Merrimack will host a live conference call and webcast today, Thursday, August 4 at 4:30 p.m., Eastern time, to provide an update on Merrimack's progress as well as a summary of these results.
MACK: 4.53 (-0.06)
Merrimack (MACK): Can the Stock Surprise in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:38PM CDT
Merrimack (MACK) is scheduled to report second-quarter 2016 results on Aug 4.
MACK: 4.53 (-0.06), IRWD: 13.26 (-0.09), LLY: 76.85 (-0.38), EXEL: 11.54 (+0.19)
Biotechnology Equities Technical Review -- Geron, Merrimack Pharma, Alnylam Pharma, and CytRx
PR Newswire - Fri Jun 17, 7:50AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Geron Corporation (NASDAQ: GERN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and CytRx Corporation (NASDAQ: CYTR). Learn more about these stocks by accessing their free trade alerts at:
MACK: 4.53 (-0.06), ALNY: 69.17 (+0.15), GERN: 2.75 (+0.02), CYTR: 0.57 (-0.01)
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 4.53 (-0.06), BIIB: 313.59 (+7.56), IDRA: 1.92 (unch), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 4.53 (-0.06), BIIB: 313.59 (+7.56), IDRA: 1.92 (unch), RTRX: 16.10 (-0.25), LGND: 106.19 (-0.85), ACOR: 24.27 (-0.07)
Merrimack Announces Positive Data on Oncology Candidate
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 3:57PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) announced results from the phase I study on pipeline candidate, MM-151.
MACK: 4.53 (-0.06), ABT: 42.09 (-0.21), JNJ: 119.32 (+0.24), PFE: 34.77 (+0.09)
Final Analysis of First-in-Human Phase 1 Study of MM-151 Shows Positive Clinical Activity in Multiple Solid Tumor Types, Including Colorectal Cancer
PR Newswire - Mon Jun 06, 6:30AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced results from the final analysis of the Phase 1 study of MM-151, a novel investigational oligoclonal epidermal growth factor receptor (EGFR) inhibitor, in patients with refractory solid tumors. These results were presented at a Poster Discussion Session at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
MACK: 4.53 (-0.06)
Merrimack/Baxalta Start Study on Colorectal Cancer Drug
Zacks Equity Research - Zacks Investment Research - Fri May 20, 1:37PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) and Baxalta Incorporated (BXLT) announced that the companies have initiated a phase I clinical study on pipeline candidate, MM-151.
MACK: 4.53 (-0.06), ABT: 42.09 (-0.21), PFE: 34.77 (+0.09), BXLT: 46.02 (-0.18)
Merrimack Announces a Leading-edge Biomarker-Selected, Multi-Arm Basket Trial that Matches Patients with Most Appropriate Combination Regimens
PR Newswire - Thu May 19, 6:05AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) announced today the initiation of a biomarker-selected, multi-arm Phase 1 clinical study in metastatic colorectal, non-small cell lung, and head and neck cancers. Merrimack's first-of-its-kind basket study will use a combination of genetic and nongenetic biomarkers to match patients to appropriate novel combinations of investigational drug regimens based on their cancer's molecular signature. This approach is expected to enable more than 95 percent of eligible patients to qualify for enrollment to one of the investigational arms of the study. Merrimack utilized its systems biology approach to identify the biomarkers and selection criteria of the study.
MACK: 4.53 (-0.06)
Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE® (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer
PR Newswire - Thu May 19, 6:00AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) and Baxalta Incorporated (NYSE: BXLT) today jointly announced the initiation of a Phase 1 clinical study of Merrimack's oligoclonal EGFR (epidermal growth factor receptor) inhibitor, MM-151, in combination with ONIVYDE® (irinotecan liposome injection) plus fluorouracil (5-FU) and leucovorin in patients with RAS wild-type metastatic colorectal cancer. Data from a prior Phase 1 study of MM-151 supports further clinical evaluation of the investigational therapy in patients with metastatic colorectal cancer. The initiation of this study advances the development path for ONIVYDE.
MACK: 4.53 (-0.06), BXLT: 46.02 (-0.18)
Merrimack to Present on Extensive Oncology Pipeline at the 2016 American Society of Clinical Oncology Annual Meeting
PR Newswire - Wed May 18, 4:10PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present on its extensive oncology pipeline at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2016 at McCormick Place, Chicago, Illinois. Final results from a Phase 1 study evaluating the safety, pharmacology and initial efficacy of MM-151 will be presented in a Poster Discussion Session. Merrimack will also present on the results from its Phase 3 NAPOLI-1 study of ONIVYDE®, as well as on multiple therapeutic candidates from its antibody engineering and antibody-directed nanotherapeutic (ADN) technology platforms in six poster sessions.
MACK: 4.53 (-0.06)
Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the AACR Precision Medicine Series
PR Newswire - Tue May 17, 3:05PM CDT
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today presented an expanded analysis of its Phase 2 study of seribantumab (MM-121) in combination with exemestane in HER2-negative, hormone receptor positive metastatic breast cancer. Top line results from this study were announced in 2014. The final analysis, as well as a poster on Merrimack's investigational companion diagnostic for seribantumab, were presented this week at the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer, in Miami, Florida.
MACK: 4.53 (-0.06)
Why Merrimack Pharmaceuticals' Stock Is Sliding Today
George Budwell, The Motley Fool - Motley Fool - Tue May 03, 10:22AM CDT
Image source: Pixabay. What : Merrimack Pharmaceuticals saw its shares drop by nearly 11% immediately after the opening bell today due to the company missing consensus for its total revenue in the first quarter of 2016. Specifically, Merrimack...
MACK: 4.53 (-0.06)
Merrimack (MACK) Posts Narrower-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:33AM CDT
Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 33 cents per share in the first quarter of 2016, narrower than both the Zacks Consensus Estimate of 39 cents and the prior-quarter loss of 41 cents.
MACK: 4.53 (-0.06), GILD: 76.89 (-0.53), AEGR: 1.60 (+0.01), BXLT: 46.02 (-0.18)
Merrimack reports 1Q loss
Automated Insights - Mon May 02, 3:15PM CDT
CAMBRIDGE, Mass. (AP) _ Merrimack Pharmaceuticals Inc. (MACK) on Monday reported a loss of $38.5 million in its first quarter.
MACK: 4.53 (-0.06)
Biotech Stocks on Investors' Radar -- Alexion Pharma, BioMarin Pharma, Merrimack Pharma, and Pacific Biosciences of California
PR Newswire - Wed Aug 31, 6:50AM CDT
Stock-Callers.com's focus shifted to Biotechnology industry which uses biological systems or living organisms for the development of biopharmaceutical drugs. Two main catalysts driving stocks in this arena are clinical and regulatory developments. Let us now review today's featured companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), and Pacific Biosciences of California Inc. (NASDAQ: PACB). Learn more about these stocks by downloading their comprehensive and free reports at:
MACK: 4.53 (-0.06), PACB: 8.28 (-0.02), BMRN: 95.73 (+0.54), ALXN: 123.67 (-1.96)
What Makes Merrimack Pharmaceuticals (MACK) a Strong Sell?
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:50AM CDT
Merrimack Pharmaceuticals (MACK) has witnessed a significant price decline in the past four weeks, and it has lately seen negative earnings estimate revisions as well.
MACK: 4.53 (-0.06)
Potash Corporation of Saskatchewan, The Hain Celestial Group, Williams Companies, Cisco Systems, and Merrimack Pharmaceuticals and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Mon Aug 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CSCO, HAIN, MACK, POT, and WMB.
MACK: 4.53 (-0.06), HAIN: 36.65 (+0.43), POT: 17.99 (+0.18), WMB: 28.40 (+0.25), CSCO: 31.83 (+0.25)
Merrimack (MACK) Q2 Loss Wider than Expected, Sales Top
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 3:02PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 40 cents per share in the second quarter of 2016, wider than the Zacks Consensus Estimate of 34 cents.
MACK: 4.53 (-0.06)
Covered Call reports for Valeant Pharmaceuticals, Merrimack Pharmaceuticals, Exelixis, Under Armour and Harman International Industries include trade ideas that offer returns of 20% or more!
PR Newswire - Fri Aug 05, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for EXEL, HAR, MACK, UA, and VRX.
MACK: 4.53 (-0.06), UA: 38.56 (-1.19), VRX: 28.76 (-0.36), HAR: 85.99 (+1.17), EXEL: 11.54 (+0.19)
Merrimack Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Aug 04, 3:01PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced its second quarter 2016 financial results. Merrimack will host a live conference call and webcast today, Thursday, August 4 at 4:30 p.m., Eastern time, to provide an update on Merrimack's progress as well as a summary of these results.
MACK: 4.53 (-0.06)
Merrimack (MACK): Can the Stock Surprise in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:38PM CDT
Merrimack (MACK) is scheduled to report second-quarter 2016 results on Aug 4.
MACK: 4.53 (-0.06), IRWD: 13.26 (-0.09), LLY: 76.85 (-0.38), EXEL: 11.54 (+0.19)
Biotechnology Equities Technical Review -- Geron, Merrimack Pharma, Alnylam Pharma, and CytRx
PR Newswire - Fri Jun 17, 7:50AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Geron Corporation (NASDAQ: GERN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and CytRx Corporation (NASDAQ: CYTR). Learn more about these stocks by accessing their free trade alerts at:
MACK: 4.53 (-0.06), ALNY: 69.17 (+0.15), GERN: 2.75 (+0.02), CYTR: 0.57 (-0.01)
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 4.53 (-0.06), BIIB: 313.59 (+7.56), IDRA: 1.92 (unch), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 4.53 (-0.06), BIIB: 313.59 (+7.56), IDRA: 1.92 (unch), RTRX: 16.10 (-0.25), LGND: 106.19 (-0.85), ACOR: 24.27 (-0.07)
Merrimack Announces Positive Data on Oncology Candidate
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 3:57PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) announced results from the phase I study on pipeline candidate, MM-151.
MACK: 4.53 (-0.06), ABT: 42.09 (-0.21), JNJ: 119.32 (+0.24), PFE: 34.77 (+0.09)
Final Analysis of First-in-Human Phase 1 Study of MM-151 Shows Positive Clinical Activity in Multiple Solid Tumor Types, Including Colorectal Cancer
PR Newswire - Mon Jun 06, 6:30AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced results from the final analysis of the Phase 1 study of MM-151, a novel investigational oligoclonal epidermal growth factor receptor (EGFR) inhibitor, in patients with refractory solid tumors. These results were presented at a Poster Discussion Session at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
MACK: 4.53 (-0.06)
Merrimack/Baxalta Start Study on Colorectal Cancer Drug
Zacks Equity Research - Zacks Investment Research - Fri May 20, 1:37PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) and Baxalta Incorporated (BXLT) announced that the companies have initiated a phase I clinical study on pipeline candidate, MM-151.
MACK: 4.53 (-0.06), ABT: 42.09 (-0.21), PFE: 34.77 (+0.09), BXLT: 46.02 (-0.18)
Merrimack Announces a Leading-edge Biomarker-Selected, Multi-Arm Basket Trial that Matches Patients with Most Appropriate Combination Regimens
PR Newswire - Thu May 19, 6:05AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) announced today the initiation of a biomarker-selected, multi-arm Phase 1 clinical study in metastatic colorectal, non-small cell lung, and head and neck cancers. Merrimack's first-of-its-kind basket study will use a combination of genetic and nongenetic biomarkers to match patients to appropriate novel combinations of investigational drug regimens based on their cancer's molecular signature. This approach is expected to enable more than 95 percent of eligible patients to qualify for enrollment to one of the investigational arms of the study. Merrimack utilized its systems biology approach to identify the biomarkers and selection criteria of the study.
MACK: 4.53 (-0.06)
Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE® (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer
PR Newswire - Thu May 19, 6:00AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) and Baxalta Incorporated (NYSE: BXLT) today jointly announced the initiation of a Phase 1 clinical study of Merrimack's oligoclonal EGFR (epidermal growth factor receptor) inhibitor, MM-151, in combination with ONIVYDE® (irinotecan liposome injection) plus fluorouracil (5-FU) and leucovorin in patients with RAS wild-type metastatic colorectal cancer. Data from a prior Phase 1 study of MM-151 supports further clinical evaluation of the investigational therapy in patients with metastatic colorectal cancer. The initiation of this study advances the development path for ONIVYDE.
MACK: 4.53 (-0.06), BXLT: 46.02 (-0.18)
Merrimack to Present on Extensive Oncology Pipeline at the 2016 American Society of Clinical Oncology Annual Meeting
PR Newswire - Wed May 18, 4:10PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present on its extensive oncology pipeline at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2016 at McCormick Place, Chicago, Illinois. Final results from a Phase 1 study evaluating the safety, pharmacology and initial efficacy of MM-151 will be presented in a Poster Discussion Session. Merrimack will also present on the results from its Phase 3 NAPOLI-1 study of ONIVYDE®, as well as on multiple therapeutic candidates from its antibody engineering and antibody-directed nanotherapeutic (ADN) technology platforms in six poster sessions.
MACK: 4.53 (-0.06)
Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the AACR Precision Medicine Series
PR Newswire - Tue May 17, 3:05PM CDT
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today presented an expanded analysis of its Phase 2 study of seribantumab (MM-121) in combination with exemestane in HER2-negative, hormone receptor positive metastatic breast cancer. Top line results from this study were announced in 2014. The final analysis, as well as a poster on Merrimack's investigational companion diagnostic for seribantumab, were presented this week at the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer, in Miami, Florida.
MACK: 4.53 (-0.06)
Why Merrimack Pharmaceuticals' Stock Is Sliding Today
George Budwell, The Motley Fool - Motley Fool - Tue May 03, 10:22AM CDT
Image source: Pixabay. What : Merrimack Pharmaceuticals saw its shares drop by nearly 11% immediately after the opening bell today due to the company missing consensus for its total revenue in the first quarter of 2016. Specifically, Merrimack...
MACK: 4.53 (-0.06)
Merrimack (MACK) Posts Narrower-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:33AM CDT
Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 33 cents per share in the first quarter of 2016, narrower than both the Zacks Consensus Estimate of 39 cents and the prior-quarter loss of 41 cents.
MACK: 4.53 (-0.06), GILD: 76.89 (-0.53), AEGR: 1.60 (+0.01), BXLT: 46.02 (-0.18)
Merrimack reports 1Q loss
Automated Insights - Mon May 02, 3:15PM CDT
CAMBRIDGE, Mass. (AP) _ Merrimack Pharmaceuticals Inc. (MACK) on Monday reported a loss of $38.5 million in its first quarter.
MACK: 4.53 (-0.06)
(0)
(0)Scroll down for more posts ▼